Exeltis has received acceptance from the US Food and Drug Administration (FDA) of the filing of Slinda® (4mg Drospirenone-only pill), the novel oral contraceptive developed by the company. The Prescription Drug User Fee Act (PDUFA) date is expected during the 27 May of 2019.
This Friday, Exeltis teamed up with the National Resilience Institute to reward Irene Villa, Teresa Silva, Eduardo Palomino and María Carmen Villena, Maricruz Rubio and Diego Barreno for their outstanding ability to overcome adversity and their positive attitude to life.
A total of 42.7% of women would choose a flexible extended regimen in order to reduce and have greater control over their menses, according to the Flexo study undertaken by a team of Spanish scientists in cooperation with the Spanish Contraception Society.
The pharmaceutical group Insud Pharma has just kicked off the second round of its startup programme #CHEMOSTART!, which aims to help get innovative health projects off the ground and offer additional support to projects which are already up and running.
Through an agreement with Devicare, Exeltis Spain is to commercialise Lit-Control, a first-in-class medical solution which monitors urinary pH levels to treat recurring urinary diseases, such as renal lithiasis
Renal lithiasis alone affects 2.2 million people in Spain, with 325,000 new cases diagnosed every year, and is known for causing acute bouts intense pain (renal colic)
Exeltis and the entire Insud Pharma group have once again been rated “very good” in the 2017-2020 edition of the Spanish government’s Profarma Programme, thanks to our contribution to modernising the sector, our commitment to R&D and our clear focus on activities that add value.
The Autonomous University of Madrid (UAM) and the multinational pharmaceutical company Insud Pharma are launching the UAM-Insud Pharma Programme of Innovation Challenges with a Strong Social Impact for biomedical innovation with an open innovation approach that enables the transfer of knowledge through science excellence to overcome some of the specific challenges of our society.
The finalists in the #Chemostart programme designed by our Group presented their projects to a round table of investors.
We have become increasingly aware in the past few days of the very severe situation in Guatemala following the eruption of the country’s Volcano of Fire. Through our subsidiary Exeltis Guatemala, we wanted to lend our support and help the victims by donating essential medicines to treat the most common conditions in these kinds of disasters.
“Understanding epilepsy makes us equal” is the title of a comic produced by Exeltis Spain together with the paediatric neurologist, doctor Adrián García Ron, to improve understanding and help to normalise this neurological disorder, especially among the most vulnerable group: children.